이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section (dip-Caesar)

2017년 3월 28일 업데이트: Jena University Hospital

Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section (Dip-Caesar)

A medical approach that warrants continuous and reliable local administration of non-opioid analgesic drugs might substantially improve post-surgery pain management in CS, while decreasing the necessity of staff-dependent invasive procedures and the probability of untoward effects following systemic drug exposure. ReadyfusOR® is a formulation comprising a Ropivacain-loaded single-use pump which has been approved for regional application of the analgesic drug, also comprising obstetric interventions. There is, however, scarce scientific information on the efficacy and benefit of this anesthetic drug formulation for pain management following CS by means of continuous wound infiltration.

연구 개요

상태

빼는

정황

개입 / 치료

상세 설명

During the past decades the rate of Caesarean sections has increased considerably, with Germany following the global trend. When compared to other surgical interventions, Caesarean section is perceived as very painful. Patient-controlled analgesia (PCA) is associated with significantly higher opioid dosage, as compared to cases where the same medication is administered on patient's request as a bolus by the attending staff. Conceivably, patients using PCA reported less painful sensations. Nonetheless, several patients and physicians express reservations concerning the use of opioids for pain management in lactating mothers. Peripheral application of local anesthetics (e.g. as wound infiltration or peripheral nerve blockade) has been shown in several settings to reduce the demand of systemic drug dosage in pain management. The intended effect, however, lasts only for a couple of hours. Feasibility of subsequent bolus drug applications is hampered by ethical concerns (being an invasive procedure) as well as staff strains and cost effectiveness considerations. Hence, a medical device that warrants continuous and reliable administration of local analgesics might substantially improve pain management in obstetric patients. ReadyfusOR® is a medical device that has been approved for use for such purposes.

This study will record the use of the Ropivacaine formulation ReadyfusOR® under real life conditions in a representative sample. Ropivacaine formulation ReadyfusOR® is established as a standard procedure for diminution of post-surgery pain in the Department of Obstetrics of the Jena University Hospital. The gathered information will be used to augment the knowledge about outcomes and safety of the Ropivacaine formulation ReadyfusOR® using for treatment of patients undergoing Caesarean section. Analgesic efficacy will be monitored at defined intervals over an observation period of 48 h post-surgery using patient's subjective ratings of spontaneous and strain-induced pain perception, as well as the demand of auxiliary dosing of standard analgesic treatment.

At the end of surgery and prior to closure of the abdomen the drug infusion catheter of Readyfusor® is inserted subfascially. An initial priming dose of 10 mL of 2mg/mL ropivacain will be injected through the catheter. After the catheter has been primed with the initial loading dose, the Readyfusor® is activated by the surgeon or nurse in the operating room and connected to the wound catheter. As described in the product information, the wound edges are supplied with Ropivacain over 48 h at a rate of 10 mg/hour (5 mL/hr). During the first 48 h post-surgery patients receive standard pain management with Ibuprofen at doses of 600 mg administered in intervals of 8 hours. If the patients are free of pain Ibuprofen application can be reduced as needed. The synthetic opioid Piritramide is used as pain medication on demand for patients who report mild to severe pain defined as 5 or more points on a 10-point-Numeric Rating Scale (NRS). In either available application option - as PCA or a bolus injection by the attending nurse - the dose of Piritramide is limited to 30 mg over 4 hours and each single application are limited to 3mg every 10 minutes.

Maximal intensity of pain at rest and pain due to mobilization (first standing up) will be assessed at intervals of 12, 24 and 48 h after treatment introduction by means of patient's statements plotted on individual numeric rating scales for each endpoint. The primary endpoint focuses on assessing the perceived spontaneous pain intensity at 24 h post-surgery.

Further characterization of the pain-relieving effect of ReadyfusOR® will be provided by the records on the fractional doses of the auxiliary opioid analgesic Piritramide administered within 12, 24 and 48 h post-surgery. The individual time needed for the recovery of mobility will provide an additional tool for treatment effect evaluation.

Finally, NRS-recorded patient's ratings on subjectively perceived satisfaction with the post-surgical pain management will be evaluated.

연구 유형

관찰

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

샘플링 방법

비확률 샘플

연구 인구

Patients undergoing delivery by elective or emergent Caesarean section

설명

Inclusion Criteria:

  • Elective or emergent Caesarean section under spinal or general anesthesia
  • Medically indicated necessity of post-surgery analgesia
  • Signed informed consent
  • Body Mass Index above 20 and below 35

Exclusion Criteria:

  • Wound drainage application following surgery
  • Epidural catheter following surgery
  • Planned concurrent surgical Intervention
  • Chronic high-dose opioid use (>20 mg oxycodone equivalent daily) over more than 4 weeks prior to surgery
  • History of, suspected or present addiction or abuse of illicit drug(s), prescription medicine(s) or alcohol during the preceding 2 years
  • Intolerance or allergy to any of the medications planned for use
  • Concurrent painful physical conditions that may require analgesic Treatment
  • Current or planned administration of Long-acting Opioids, selective Serotonin reuptake Inhibitors, gabapentin, pregabalin or duloxetine within 30 days preceding and7or following surgery
  • Use of systemic glucocorticoids (except for induction of fetal lung maturation) within 1 month prior to enrollment
  • Uncontrolled anxiety, schizophrenia or other psychiatric conditions which could interfere with the compliance and subjective assessment of Treatment effects (decision at the discretion of the investigator)
  • Inability to operate devices for Patient-controlled analgesia

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Maximal perceived pain intensity 24 h after surgery
기간: 24 hours
Subjectively rated pain perception by a 10-point-numeric rating scale
24 hours

2차 결과 측정

결과 측정
측정값 설명
기간
Perceived pain at rest over 12 h after surgery
기간: 12 hours
Subjectively rated pain perception by a 10-point-numeric rating scale
12 hours
Perceived pain at mobilization over 12 h after surgery
기간: 12 hours
Subjectively rated pain perception by a 10-point-numeric rating scale
12 hours
Perceived pain at rest over 24 h after surgery
기간: 24 hours
Subjectively rated pain perception by a 10-point-numeric rating scale
24 hours
Perceived pain at mobilization over 24 h after surgery
기간: 24 hours
Subjectively rated pain perception by a 10-point-numeric rating scale
24 hours
Perceived pain at rest over 48 h after surgery
기간: 48 hours
Subjectively rated pain perception by a 10-point-numeric rating scale
48 hours
Perceived pain at mobilization over 48 h after surgery
기간: 48 hours
Subjectively rated pain perception by a 10-point-numeric rating scale
48 hours
Opioid demand over 12 h after surgery
기간: 12 hours
Cumulative dosis of Piritramide administered on demand over 12 hours
12 hours
Opioid demand over 24 h after surgery
기간: 24 hours
Cumulative dosis of Piritramide administered on demand over 24 hours
24 hours
Opioid demand over 48 h after surgery
기간: 48 hours
Cumulative dosis of Piritramide administered on demand over 48 hours
48 hours
Satisfaction with pain management 24 h after surgery
기간: 24 hours
Subjectively rated degree of satisfaction with analgesia by 10-point numeric Rating scale
24 hours

기타 결과 측정

결과 측정
측정값 설명
기간
Adverse events and adverse drug reactions
기간: 48 hours
Registration of adverse avents and adverse drug reactions over the duration of Ropivacaine administration
48 hours

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Ekkehard Schleussner, MD, Department of Obstetrics, Jena University Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2016년 8월 1일

기본 완료 (실제)

2016년 8월 1일

연구 완료 (실제)

2016년 8월 1일

연구 등록 날짜

최초 제출

2016년 7월 5일

QC 기준을 충족하는 최초 제출

2016년 7월 8일

처음 게시됨 (추정)

2016년 7월 11일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 3월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 3월 28일

마지막으로 확인됨

2017년 3월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Dissemination of individual participant data is not planned

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

통증에 대한 임상 시험

Ropivacaine에 대한 임상 시험

구독하다